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A genetic mutation that protects against HIV infection increases 
the risk of developing clinical West Nile virus (WNV) infection, 
according to Glass and colleagues on page 35.
The mutation in question is a 32-bp deletion in a gene that 
encodes the chemokine receptor CCR5, which was identified in 
1996 as a cellular coreceptor for HIV. Individuals homozygous for 
this mutation (CCR5∆32) are highly resistant to HIV infection, 
even when repeatedly exposed to the virus. This resistance was 
the theoretical basis for the development of therapeutic CCR5 
inhibitors, several of which are now in clinical trials. CCR5 
seemed like an ideal drug target, as people missing the receptor 
were healthy and no diseases or infections were known to be 
more frequent or severe in individuals homozygous for CCR5∆32. 
Mice appeared to be equally unfazed by the lack of CCR5.
But new evidence suggests that the lack of CCR5 is not 
completely innocuous. This group recently showed that infection 
with WNV—a mosquito-borne virus that has spread rapidly across 
the United States since 1999, often causing fatal encephalitis—
was uniformly fatal in mice lacking CCR5. This finding prompted 
the group to look for the CCR5∆32 allele in two cohorts of 
patients in the United States who had symptomatic WNV 
infections. They now report that 4–5% of the infected individuals 
were homozygous for the CCR5∆32 allele, compared with less 
than 1% of the general 
population, suggesting 
that the lack of CCR5 puts 
people at risk for 
developing clinical WNV 
infections. The magnitude 
of this risk is comparable 
to the magnitude of 
protection against HIV 
that is conferred by this 
genotype. It remains to be 
tested whether CCR5-
deficient humans, like 
mice, develop more severe 
disease because fewer 
protective immune cells gain access to the brain.
This study identifies not only the first genetic susceptibility 
factor for WNV infection but also the first association of the 
CCR5∆32 allele with susceptibility to an infectious disease. These 
data might also raise a red flag for the use of CCR5 inhibitors in 
HIV-infected patients—at least in areas endemic for WNV—as 
such inhibitors might increase the recipients’ vulnerability to 
severe WNV infection. 
Individuals homozygous for the 
CCR5∆32 allele are more likely to suffer 
from fatal West Nile Virus infection.
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A study on page 239 shows that death-inducing T cells kill smooth muscle cells in atherosclerotic plaques. Sato 
et al. show that this lethal T cell activity is heightened in patients with heart disease, which could destabilize 
the plaques in these patients and make them more prone to rupture.
The narrowing of arteries is a natural process caused by the gradual deposition of fat and cholesterol into artery 
walls. The buildup of arterial plaques (atherosclerosis) is a long-term process that, for some, culminates in acute 
coronary syndromes (ACSs) such as heart attack and cardiac arrest. These acute attacks are caused by the sudden 
rupture of atherosclerotic plaques—an event that may happen more readily in some individuals than in others.
Plaques that contain immune cells such as macrophages and T cells are the most vulnerable to rupture, al-
though the mechanism behind this observation is not well understood. Now, Sato and colleagues show that 
CD4+ T cells that infiltrate atherosclerotic plaques trigger the death of vascular smooth muscle cells (VSMCs), 
a process proposed to destabilize the plaques.
The plaque-infiltrating T cells expressed high levels of TRAIL, a death receptor 
normally used by T cells and NK cells to destroy cancerous cells. The expression of 
this receptor was required for T cells to induce apoptosis in VSMCs (which expressed 
the TRAIL receptor DR5) both in vitro and in vivo. CD4+ T cells from patients with 
ACS expressed higher levels of TRAIL when activated and were more adept at trig-
gering VSMC apoptosis in vitro compared with T cells from healthy individuals, pos-
sibly explaining why these individuals developed acute disease while others were 
spared. What causes plaque-residing VSMCs to express DR5 and why T cells infil-
trate the plaques in some individuals is not yet known.
These results demonstrate that the TRAIL pathway—previously thought to in-
duce death only in cancer cells—can also trigger apoptosis in nontransformed cells. A 
recombinant form of TRAIL is currently in clinical trials for the treatment of certain 
cancers, a therapeutic approach that might need reevaluation in light of its potential 
negative effects on patients with atherosclerosis. 
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